Advanced bile acid-based multi-compartmental microencapsulated pancreatic ß-cells integrating a polyelectrolyte-bile acid formulation, for diabetes treatment.

QR Code

Advanced bile acid-based multi-compartmental microencapsulated pancreatic ß-cells integrating a polyelectrolyte-bile acid formulation, for diabetes treatment.

This study utilized the Seahorse Analyzer to examine the effect of the bile acid ursodeoxycholic acid (UDCA), on the morphology, swelling, stability, and size of novel microencapsulated ß-cells, in real-time. UDCA was conjugated with fluorescent compounds, and its partitioning within the microcapsul...

Full description

Bibliographic Details
Main Authors:	Mooranian, A., Negrulj, R., Chen-Tan, N., Fakhoury, M., Arfuso, F., Jones, Franca, Al-Salami, H.
Format:	Journal Article
Published:	2014
Online Access:	http://hdl.handle.net/20.500.11937/13290

Similar Items

Characterization of a novel bile acid-based delivery platform for microencapsulated pancreatic ß-cells.
by: Mooranian, Armin, et al.
Published: (2014)

Novel multicompartmental bile acid-based microcapsules for pancreatic β-cell transplantation
by: Mooranian, A., et al.
Published: (2015)

NOVEL MULTICOMPARTMENTAL BILE ACID-BASED MICROCAPSULES FOR PANCREATIC beta-CELL TRANSPLANTATION
by: Mooranian, A., et al.
Published: (2015)

An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer
by: Mooranian, Armin, et al.
Published: (2014)

Viability and topographical analysis of microencapsulated ß-cells exposed to a biotransformed tertiary bile acid: An ex vivo study
by: Mooranian, Armin, et al.
Published: (2016)

Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment
by: Mooranian, Armin, et al.
Published: (2015)

Novel artificial cell microencapsulation of a complex gliclazide-deoxycholic bile acid formulation: A Characterization Study
by: Mooranian, Armin, et al.
Published: (2014)

Primary Bile Acid Chenodeoxycholic Acid-Based Microcapsules to Examine ß-cell Survival and the Inflammatory Response
by: Mooranian, A., et al.
Published: (2016)

The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: potential applications in diabetes: a characterization study
by: Mooranian, A., et al.
Published: (2015)

Novel artificial cell microencapsulation of probucol and bile acids in diabetes mellitus
by: Mooranian, Armin
Published: (2018)

Release and swelling studies of an innovative antidiabetic-bile acid microencapsulated formulation, as a novel targeted therapy for diabetes treatment (vol 32, pg 151, 2014)
by: Mooranian, A., et al.
Published: (2015)

An advanced microencapsulated system: a platform for optimized oral delivery of antidiabetic drug-bile acid formulations
by: Mooranian, A., et al.
Published: (2015)

Potentials and Limitations of Bile Acids in Type 2 Diabetes Mellitus: Applications of Microencapsulation as a Novel Oral Delivery System
by: Negrulj, Rebecca, et al.
Published: (2013)

New biotechnological microencapsulating methodology utilizing individualized gradient-screened jet laminar flow techniques for pancreatic ß-cell delivery: bile acids support cell energy-generating mechanisms
by: Mooranian, A., et al.
Published: (2017)

Electrokinetic potential-stabilization by bile acid-microencapsulating formulation of pancreatic ß-cells cultured in high ratio poly-L-ornithine-gel hydrogel colloidal dispersion: applications in cell-biomaterials, tissue engineering and biotechnological applications
by: Mooranian, A., et al.
Published: (2017)

The impact of allylamine-bile acid combinations on cell delivery microcapsules in diabetes
by: Mooranian, Armin, et al.
Published: (2016)

The applications of microencapsulated formulation of gliclazide and bile acids in Type-1 diabetes mellitus
by: Mathavan, Sangeetha
Published: (2017)

Flow vibration-doubled concentric system coupled with low ratio amine to produce bile acid-macrocapsules of ß-cells
by: Mooranian, Armin, et al.
Published: (2016)

Morphological, Stability, and Hypoglycemic Effects of New Gliclazide-Bile Acid Microcapsules for Type 1 Diabetes Treatment: the Microencapsulation of Anti-diabetics Using a Microcapsule-Stabilizing Bile Acid
by: Mathavan, S., et al.
Published: (2018)

The incorporation of water-soluble gel matrix into bile acid-based microcapsules for the delivery of viable ß-cells of the pancreas, in diabetes treatment: biocompatibility and functionality studies.
by: Mooranian, A., et al.
Published: (2015)

The roles of bile acids and applications of microencapsulation technology in treating Type 1 diabetes mellitus
by: Woodhams, L., et al.
Published: (2017)

Designing anti-diabetic ß-cells microcapsules using polystyrenic sulfonate, polyallylamine and a tertiary bile acid: Morphology, bioenergetics and cytokine analysis.
by: Mooranian, A., et al.
Published: (2016)

Alginate-combined cholic acid increased insulin secretion of microencapsulated mouse cloned pancreatic ß cells
by: Mooranian, A., et al.
Published: (2017)

Application of bile acids in drug formulation and delivery
by: Stojancevic, M., et al.
Published: (2014)

Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes
by: Negrulj, R., et al.
Published: (2015)

Influence of Biotechnological Processes, Speed of Formulation Flow and Cellular Concurrent Stream-Integration on Insulin Production from ß-cells as a Result of Co-Encapsulation with a Highly Lipophilic Bile Acid
by: Mooranian, A., et al.
Published: (2017)

Bile acids and probiotics could help treating diabetes
by: Calasan, J., et al.
Published: (2012)

Diabetes development increased concentrations of the conjugated bile acid, taurocholic acid in serum, while treatment with microencapsulated-taurocholic acid exerted no hypoglycaemic effects
by: Mathavan, S., et al.
Published: (2017)

Bile acids for probucol formulations applications in drug induced ototoxicity
by: Ionescu, Corina Mihaela
Published: (2024)

Multicompartmental, multilayered probucol microcapsules for diabetes mellitus: Formulation characterization and effects on production of insulin and inflammation in a pancreatic ß-cell line
by: Mooranian, A., et al.
Published: (2015)

Eudragit®-based microcapsules of probucol with a gut-bacterial processed secondary bile acid
by: Mooranian, A., et al.
Published: (2018)

Potential Applications of Gliclazide in Treating Type 1 Diabetes Mellitus: Formulation with Bile Acids and Probiotics
by: Mikov, M., et al.
Published: (2017)

The role of the bile acid chenodeoxycholic acid in the targeted oral delivery of the anti-diabetic drug gliclazide, and its applications in type 1 diabetes
by: Mathavan, S., et al.
Published: (2015)

Extraction and quantitative determination of bile acids in feces
by: Shafaei, A., et al.
Published: (2021)

Pharmacological Applications of Bile Acids and Their Derivatives in the Treatment of Metabolic Syndrome
by: Danic, M., et al.
Published: (2018)

Biological Assessments of Encapsulated Pancreatic ß-Cells: Their Potential Transplantation in Diabetes
by: Mooranian, Armin, et al.
Published: (2016)

Rethinking the bile acid/gut microbiome axis in cancer
by: Phelan, J., et al.
Published: (2017)

Bile acids and their derivatives as potential modifiers of drug release and pharmacokinetic profiles
by: Pavlovic, N., et al.
Published: (2018)

High-Loading Dose of Microencapsulated Gliclazide Formulation Exerted a Hypoglycaemic Effect on Type 1 Diabetic Rats and Incorporation of a Primary Deconjugated Bile Acid, Diminished the Hypoglycaemic Antidiabetic Effect
by: Golocorbin-Kon, S., et al.
Published: (2017)

Probiotics decreased the bioavailability of the bile acid analog, monoketocholic acid, when coadministered with gliclazide, in healthy but not diabetic rats
by: Al-Salami, Hani, et al.
Published: (2012)

Cannot write session to /tmp/vufind_sessions/sess_p4907vijn583v8pu8tqg4dabil